Journal article

Publication year: 2020

Pages: 30-37

Journal: Urology

Volume number: 145

ISSN: 0090-4295

eISSN: 1527-9995

DOI Link: https://doi.org/10.1016/j.urology.2020.06.039

Publisher: Elsevier

Abstract: 
Circulating tumor cells (CTCs) are considered to be promising biomarkers in malignant diseases. Recently, molecular profiles of CTCs in prostate cancer (PCa) and the role of CTCs in neoadjuvant chemotherapy and transurethral resections of bladder cancer (BCa) are intensely studied. However, localized PCa and nonmuscle-invasive BCa are less investigated and discussed. Moreover, the benefit and feasibility of clinical applications of CTCs should be critically questioned and reevaluated. This review focuses mainly on clinical issues and lesser on methodologies, and summarizes the quintessence of available works dealing with clinical applications of CTCs in PCa and BCa management. (C) 2020 Elsevier Inc.

Harvard Citation style: Yan, H., Dittmar, F., Schagdarsurengin, U. and Wagenlehner, F. (2020) The Clinical Application and Potential Roles of Circulating Tumor Cells in Bladder Cancer and Prostate Cancer, Urology, 145, pp. 30-37. https://doi.org/10.1016/j.urology.2020.06.039

APA Citation style: Yan, H., Dittmar, F., Schagdarsurengin, U., & Wagenlehner, F. (2020). The Clinical Application and Potential Roles of Circulating Tumor Cells in Bladder Cancer and Prostate Cancer. Urology. 145, 30-37. https://doi.org/10.1016/j.urology.2020.06.039